Wall Street Journal
US · 7 hrs ago
✦ 78✓ Factual
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics - WSJ
78Quality
0Ratings
0Comments
AI Analysis
Quality 78/100
Partisan intensity 15/100
ObjectivePartisan
Low partisan intensity — consistent with factual reporting✓ Fair headline
Swiss pharmaceutical company Roche has entered into a $2.3 billion deal with biotech firm Nurix Therapeutics to develop and commercialize blood-cancer drugs.
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics - WSJ
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics WSJ
Discussion 0 comments
Sort:
?
No comments yet — be the first to start the discussion!